Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + omalizumab
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of rituximab and omalizumab used primarily for treating refractory bullous pemphigoid. Rituximab is a monoclonal anti-CD20 antibody that depletes B cells, while omalizumab is an IgE-neutralizing antibody that prevents IgE from binding to its receptors on inflammatory cells. The combination appears to work synergistically, with studies showing a 70% durable complete response rate in bullous pemphigoid patients who failed conventional therapies.
- Brand names
- XolairRituxan
- Other names
- RTX + OMZOMZ + RTX
02
Targets
Beyond the preview
Go deeper on rituximab + omalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + omalizumab.